Diagnosis and management of type 2 diabetes;Diagnóstico y control de la diabetes mellitus tipo 2

Atencion Primaria

Volumn 42, Issue SUPPL. 1, 2010, Pages 2-8

  Espino, Javier Díez ^a,b,c  

^a EAP Humanes   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c Grupo de Trabajo de Diabetes SemFYC   (Spain)

Author keywords

Diagnosis; Glycemic control; HbA1c; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

CARDIOVASCULAR RISK; DIAGNOSTIC TEST; DISEASE DURATION; FALSE NEGATIVE RESULT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH PROGRAM; HUMAN; HYPOGLYCEMIA; LIFE EXPECTANCY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY DIABETES MELLITUS; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

EID: 78649250133     PISSN: 02126567     EISSN: 15781275     Source Type: Journal    
DOI: 10.1016/S0212-6567(10)70002-0     Document Type: Article

References (38)

1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Diabetes Care 20 1997 1183 1197
2. D. Vistisen, S. Colagiuri, K. Borch-Johnsen DETECT-2 Collaboration Bimodal distribution of glucose is not universally useful for diagnosing diabetes Diabetes Care 32 2009 397 403
3. World Health Organization Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1. Diagnosis and Classification of Diabetes Mellitus 1999 World Health Organization Geneva
4. International Expert Committee International Expert Committee report on the Role of the A1C assay in the diagnosis of diabetes Diabetes Care 32 2009 1327 1334
5. American Diabetes Association Standards of medical care in diabetes - 2010 Diabetes Care 33 Suppl 1 2010 11 61
6. Disponible en: http://www.seen.es/seen/Cliente?id-aplic=58&id-tabla= 47&idpv=3.
7. Disponible en: http://www.aace.com/pub/pdf/guidelines/ AACEpositionA1cfeb2010.pdf.
8. C.C. Cowie, K.F. Rust, D.D. Byrd-Holt, E.W. Gregg, E.S. Ford, and L.S. Geiss Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006 Diabetes Care 33 2010 562 568
9. C.K. Kramer, M.R. Araneta, and E. Barrett-Connor A1C and diabetes diagnosis: The Rancho Bernardo Study Diabetes Care 33 2010 101 103
10. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus The Diabetes Control and Complications Trial Research Group N Engl J Med. 329 1993 977 986
11. Y. Ohkubo, H. Kishikawa, E. Araki, T. Miyata, S. Isami, and S. Motoyoshi Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study Diabetes Res Clin Pract. 28 1995 103 117
12. C. Stettler, S. Allemann, P. Jüni, C.A. Cull, R.R. Holman, and M. Egger Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials Am Heart J. 152 2006 27 38
13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet. 352 1998 837 853
14. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) UK Prospective Diabetes Study (UKPDS) Group Lancet. 352 1998 854 865
15. H.C. Gerstein, M.E. Miller, R.P. Byington, D.C. Goff Jr, J.T. Bigger, J.B. Buse Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes N Engl J Med. 358 2008 2545 2559
16. A. Patel, S. MacMahon, J. Chalmers, B. Neal, L. Billot, M. Woodward ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med. 358 2008 2560 2572
17. W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emannele, and P.D. Reaven Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med. 360 2009 129 139
18. F.M. Turnbull, C. Abraira, R.J. Anderson, R.P. Byington, J.P. Chalmers, and W.C. Duckworth Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia. 52 2009 2288 2298
19. K.K. Ray, S.R. Seshasai, S. Wijesuriya, R. Sivakumaran, S. Nethercott, and D. Preiss Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Lancet. 373 2009 1765 1772
20. C.J. Currie, J.R. Peters, A. Tynan, M. Evans, R.J. Heine, and O.L. Bracco Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study Lancet. 375 2010 481 489
21. M.E. Miller, D.E. Bonds, H.C. Gerstein, E.R. Seaquist, R.M. Bergenstal, J. Calles-Escandon ACCORD Investigators The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study BMJ. 340 2010 b5444
22. R.R. Holman, S.K. Paul, M.A. Bethel, and D.R. Matthews Neil HAW: 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med. 359 2008 1577 1589
23. P. Gaede, H. Lund-Andersen, H.H. Parving, and O. Pedersen Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med. 358 2008 580 591
24. Disponible en: http://www.redgedaps.es.
25. H.W. Rodbard, P.S. Jellinger, J.A. Davidson, D. Einhorn, A.J. Garber, and G. Grunberger Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract. 15 2009 540 559
26. National Institute for Health and Clinical Excellence (2009) Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. Disponible en: http://www.nice.org.uk/CG87ShortGuideline.
27. T. Mazzone Hyperglycaemia and coronary heart disease: the meta picture Lancet. 373 2009 1737 1738
28. Guía para el control de la glucosa posprandial. Disponible en: http://www.idf.org/webdata/docs/Spanish-GMPG%20Final%20110108.pdf.
29. A. Ceriello The post-prandial state and cardiovascular disease: relevance to diabetes mellitus Diabetes Metab Res Rev. 16 2000 125 132
30. L. Monnier, H. Lapinski, and C. Colette Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c) Diabetes Care 26 2003 881 885
31. M. Coutinho, H.C. Gerstein, Y. Wang, and S. Yusuf The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12. 4 years Diabetes Care 22 1999 233 240
32. F. De Vegt, J.M. Dekker, H.G. Ruhé, C.D. Stehouver, G. Nijpels, and L.M. Bouter Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study Diabetologia. 42 1999 926 931
33. The absence of a glycemic threshold for the development of long term complications: the perspective of the Diabetes Control and Complications Trial Diabetes. 45 1996 1289 1298
34. The DECODE study group on behalf of the Europe on Diabetes Epidemiology Group Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group Lancet. 354 1999 617 621
35. J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA. 290 2003 486 494
36. I. Raz, P.W. Wilson, K. Strojek, I. Kowalska, V. Bozikov, and A.K. Gitt Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial Diabetes Care 32 2009 381 386
37. Guía global para la diabetes tipo 2. Disponible en: http://www.idf.org/webdata/docs/GGTD%20Spanish%20Final%20version%203107.pdf.
38. Díez Espino J. HbA1c en los pacientes diabéticos tipo 2: ¿cuál ha de ser el objetivo? FMC. Form Med Contin Aten Prim. 2010. En prensa.